Etiologic Mechanisms in Diabetic Retinopathy

Retina: Fourth Edition

Volumn 2-3, Issue , 2005, Pages 1241-1270

  Frank, Robert N ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84917332024     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-02598-0.50072-0     Document Type: Chapter

References (277)

1. Linner E, Svanborg A, Zelander T Retinal and renal lesions of diabetic type, without obvious disturbances in glucose metabolism, in a patient with family history of diabetes. Am J Med 1965, 39:298-304.
2. Hutton WL, Snyder WB, Vaiser A, et al. Retinal microangiopathy without associated glucose intolerance. Trans Am Acad Ophthalmol Otolaryngol 1972, 76:968-980.
3. DCCT Research Group The effect of intensive treatment of diabetes in the development and progression of long-term complications in insulin-dependent diabetes. N Engl J Med 1993, 329:977-986.
4. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
5. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. Br Med J 1998, 317:703-713.
6. Frank RN, Hoffman WH, Podgor MJ, et al. Retinopathy in juvenile-onset type 1 diabetes of short duration. Diabetes 1982, 31:874-882.
7. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984, 102:520-526.
8. Palmberg P, Smith M, Waltman S, et al. The natural history of retinopathy in insulin dependent juvenile-onset diabetes. Ophthalmology 1981, 88:613-618.
9. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984, 102:527-532.
10. Aiello LM, Rand LI, Briones JC, et al. Diabetic retinopathy in Joslin Clinic patients with adult-onset diabetes. Ophthalmology 1981, 88:619-623.
11. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology 1984, 91:1464-1474.
12. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995, 102:7-16.
13. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998, 105:1801-1815.
14. Knowles HC, Guest GM, Lampe J, et al. The course of juvenile diabetes treated with unmeasured diet. Diabetes 1965, 14:239-273.
15. Klein BEK, Moss SE, Klein R Is menarche associated with diabetic retinopathy?. Diabetes Care 1990, 13:1034-1038.
16. Klein R, Klein BEK, Moss SE, et al. Retinopathy in young-onset diabetic patients. Diabetes Care 1985, 8:311-315.
17. Murphy RP, Nanda M, Plotnick L, et al. The relationship of puberty to diabetic retinopathy. Arch Ophthalmol 1990, 108:215-218.
18. Daneman D, Drash AL, Lobes LA, et al. Progressive retinopathy with improved control in diabetic dwarfism (Mauriac's syndrome). Diabetes Care 1981, 4:360-365.
19. Chantelau E, Eggert H, Seppel T, et al. Elevation of serum IGF-1 precedes proliferative diabetic retinopathy in Mauriac's syndrome (letter to the editor). Br J Ophthalmol 1997, 81:169-170.
20. Merimee TJ, Zapf J, Froesch ER Insulin-like growth factors: studies in diabetes with and without retinopathy. N Engl Med 1983, 309:527-530.
21. Meyer Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease: studies in nondiabetic and diabetic subjects. J Clin Invest 1993, 92:2620-2625.
22. Grant M, Russell B, Fitzgerald C, et al. Insulin-like growth factors in vitreous: studies in control and diabetic subjects with neovascularization. Diabetes 1986, 35:416-420.
23. Kohner EM, Hamilton AM, Joplin GF, et al. Florid diabetic retinopathy and its response to treatment by photocoagulation or pituitary ablation. Diabetes 1976, 25:104-110.
24. Grant MB, Mames RN, Fitzgerald C, et al. Insulin-like growth factor-1 acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia 1995, 36:282-291.
25. Chantelau E, Kohner EM Why some cases of retinopathy worsen when diabetic control improves. Br Med J 1997, 315:1105-1106.
26. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, et al. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J 1985, 290:811-815.
27. Lauritzen T, Larsen HW, Frost-Larsen K, et al. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet 1983, 1:200-204.
28. Blood glucose control and the evolution of diabetic retinopathy and albuminuria. N Engl J Med 1984, 311:365-372. Kroc Collaborative Study Group.
29. Lauritzen T, Frost-Larsen K, Larsen HW, et al. Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes 1985, 34(Suppl. 3):74-79.
30. Poulsen JE The Houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes 1953, 2:7-12.
31. Lundbaek K, Malmros R, Andersen HC, et al. Hypophysectomy for diabetic angiopathy: a controlled clinical trial. Symposium on the treatment of diabetic retinopathy. US Public Health Service publication no. 1890 1968, 291-311. US Government Printing Office, Washington, DC. M.F. Goldberg, S.L. Fine (Eds.).
32. Oakley NW, Jopkin GF, Kohner EM, et al. The treatment of diabetic retinopathy by pituitary implantation of radioactive yttrium. Symposium on the treatment of diabetic retinopathy. US Public Health Service publication no. 1890 1968, 317-329. US Government Printing Office, Washington, DC. M.F. Goldberg, S.L. Fine (Eds.).
33. Thrailkill KM, Quattrin T, Baker L, et al. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group. Diabetes Care 1999, 22:585-592.
34. Purvin VA, Yee RD Neuro-ophthalmic disorders in diabetes mellitus. Ocular problems in diabetes mellitus 1992, 151-178. Blackwell Scientific Publications, Boston. S.S. Feman (Ed.).
35. Smith LEH, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997, 276:1706-1709.
36. Knowler WC, Bennett PH, Ballintine EJ Increased incidence of retinopathy in diabetics with elevated blood pressure: a six-year follow-up study in Pima Indians. N Engl J Med 1980, 302:645-650.
37. Kornerup T Studies in diabetic retinopathy: an investigation of 1000 cases of diabetes. Acta Med Scand 1955, 153:81-101.
38. Klein R, Klein BEK, Moss SE, et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?. Arch Intern Med 1989, 149:2427-2431.
39. Klein BEK, Moss SE, Klein R Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990, 13:34-40.
40. Rand LI, Krolewski AS, Aiello LM, et al. Multiple factors in the prediction of risk of proliferative diabetic retinopathy. N Engl J Med 1985, 313:1433-1438.
41. Cruickshanks KJ, Vadheim CM, Moss SE, et al. Genetic marker associations with proliferative retinopathy in persons diagnosed with diabetes before 30 yr of age. Diabetes 1992, 41:879-885.
42. DCCT Research Group Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes 1997, 46:1829-1839.
43. Krolewski AS, Canessa M, Warram JH, et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med 1988, 318:140-145.
44. Krolewski AS, Doria A, Magre J, et al. Molecular genetic approaches to the identification of genes involved in the development of nephropathy in insulin-dependent diabetes mellitus. J Am Soc Nephrol 1992, 3(Suppl. 4):S9-S17.
45. Pettitt DJ, Saad MF, Bennett PH, et al. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (noninsulin-dependent) diabetes mellitus. Diabetologia 1990, 33:438-443.
46. Seaquist ER, Goetz FC, Rich S, et al. Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989, 320:1161-1165.
47. Ko BC, Lam KS, Wat NM, et al. An (A-C)n dinucleotide repeat polymorphic marker at the 5' end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes 1995, 44:727-732.
48. Becker B Diabetes and glaucoma. Vascular complications of diabetes mellitus 1967, 43-48. Mosby-Year Book, St Louis. S.J. Kimura, W.M. Caygill (Eds.).
49. Jain IS, Luthra CL, Das T Diabetic retinopathy and its relation to errors of refraction. Arch Ophthalmol 1967, 77:59-60.
50. Aiello LM, Beetham WP, Balodimos MC, et al. Ruby laser photocoagulation in treatment of diabetic proliferating retinopathy: preliminary report. Symposium on the treatment of diabetic retinopathy. US Public Health Service publication no. 1890 1968, 437-464. US Government Printing Office, Washington, DC. M.F. Goldberg, S.L. Fine (Eds.).
51. Ashton N Oxygen and the growth and development of retinal vessels: in vivo and in vitro studies. Vascular complications of diabetes mellitus 1967, 3-32. Mosby-Year Book, St Louis. S.J. Kimura, W.M. Caygill (Eds.).
52. Patz A Studies on retinal neovascularization. Invest Ophthalmol Vis Sci 1980, 19:1133-1138.
53. Weiter JJ, Zuckerman R The influence of the photoreceptor-RPE complex on the inner retina: an explanation for the beneficial effects of photocoagulation. Ophthalmology 1980, 87:1133-1139.
54. Diabetic Retinopathy Study Research Group Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings. DRS report number 8. Ophthalmology 1981, 88:583-600.
55. Tattersall RB, Fajans SS A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes 1975, 24:44-53.
56. Kahn HA, Moorhead HB Statistics on blindness in the model reporting area, 1969-1970. US Department of Health, Education, and Welfare publication no. (NIH) 73-427 1973, US Government Printing Office, Washington, DC.
57. Furcht LT Critical factors controlling angiogenesis: cell products, cell matrix, and growth factors. Lab Invest 1986, 55:505-509.
58. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema, Early Treatment Diabetic Retinopathy Study report no. 1. Arch Ophthalmol 1985, 103:1796-1806.
59. Seltzer HS A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972, 21:976-979.
60. Cunha-Vaz JG, Maurice DM The active transport of fluorescein by the retinal vessels and the retina. J Physiol (Lond) 1967, 191:467-486.
61. Maurice DM A new objective fluorophotometer. Exp Eye Res 1963, 2:33-38.
62. Waltman SR, Kaufman HE A new objective slit lamp fluorophotometer. Invest Ophthalmol 1970, 9:247-249.
63. Cuhna-Vaz JG, Fonseca JR, Abreu JF, et al. A follow-up study by vitreous fluorophotometry of early retinal involvement in diabetes. Am J Ophthalmol 1978, 86:467-473.
64. Krupin T, Waltman SR, Scharp DW, et al. Ocular fluorophotometry in streptozotocin diabetes mellitus in the rat: effect of pancreatic islet isografts. Invest Ophthalmol Vis Sci 1979, 18:1185-1190.
65. Waltman SR, Santiago J, Krupin T, et al. Vitreous fluorophotometry and blood-sugar control in diabetics. Lancet 1979, 2:1068.
66. Klein R, Wallow IH, Ernest JT Fluorophotometry. III. Streptozotocin-treated rats and rats with pancreatectomy. Arch Ophthalmol 1980, 98:2235-2237.
67. Prager TC, Chu HH, Garcia CA, et al. The use of vitreous fluorophotometry to distinguish between diabetics with and without observable retinopathy: effect of vitreous abnormalities on the measurement. Invest Ophthalmol Vis Sci 1983, 24:57-65.
68. Grunwald JE, Brucker AJ, Braunstein SN, et al. Strict metabolic control and retinal blood flow in diabetes mellitus. Br J Ophthalmol 1994, 78:598-604.
69. Grunwald JE, Brucker AJ, Petrig BL, et al. Retinal blood flow regulation and the clinical response to panretinal photocoagulation in proliferative diabetic retinopathy. Ophthalmology 1989, 96:1518-1522.
70. Grunwald JE, Riva CE, Brucker AJ, et al. Altered retinal vascular response to 100% oxygen breathing in diabetes mellitus. Ophthalmology 1984, 91:1447-1452.
71. Grunwald JE, Riva CE, Martin DB, et al. Effect of an insulin-induced decrease in blood glucose on the human diabetic retinal circulation. Ophthalmology 1987, 94:1614-1620.
72. Grunwald JE, Riva CE, Sinclair SH, et al. Laser Doppler velocimetry study of retinal circulation in diabetes mellitus. Arch Ophthalmol 1986, 104:991-996.
73. Riva CE, Feke GT Laser Doppler velocimetry in the measurement of retinal blood flow. The biomedical laser technology and clinical applications 1981, 135-161. Springer-Verlag, New York. L. Goldman (Ed.).
74. Bursell SE, Clermont AC, Kinsley BT, et al. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci 1996, 37:886-897.
75. Shiba T, Inoguchi T, Sportsman JR, et al. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 1993, 265:783-793.
76. Chakravarthy U, Hayes RG, Stitt AW, et al. Endothelin expression in ocular tissues of diabetic and insulin-treated rats. Invest Ophthalmol Vis Sci 1997, 38:2144-2151.
77. Loebl M, Riva CE Macular circulation and the flying corpuscles phenomenon. Ophthalmology 1978, 85:911-917.
78. Sinclair SH, Grunwald JE, Riva CE, et al. Retinal vascular autoregulation in diabetes mellitus. Ophthalmology 1982, 89:748-750.
79. Ernest JT, Goldstick TK, Engerman RL Hyperglycemia impairs retinal oxygen autoregulation in normal and diabetic dogs. Invest Ophthalmol Vis Sci 1983, 24:985-989.
80. 2 mapping. Invest Ophthalmol Vis Sci 1996, 37:2089-2098.
81. Berkowitz BA, McDonald C, Ito Y, et al. Measuring the human retinal oxygenation response to a hyperoxic challenge using MRI: eliminating blinking artifacts and demonstrating proof of concept. Magn Reson Med 2001, 46:412-416.
82. Berkowitz BA, Wilson CA Quantitative mapping of ocular oxygenation using magnetic resonance imaging. Magn Reson Med 1995, 33:579-581.
83. Patz A, Maumenee AE Studies on diabetic retinopathy. I. Retinopathy in a dog with spontaneous diabetes mellitus. Am J Ophthalmol 1962, 54:532-541.
84. Engerman R, Finkelstein D, Aguirre G, et al. Ocular complications. Diabetes 1982, 31(Suppl. 1):82-88.
85. Engerman RL, Davis MD, Bloodworth JMB Retinopathy in experimental diabetes: its relevance to diabetic retinopathy in man. Diabetes 1971, Excerpta Medica, Amsterdam. R.R. Rodriguez, J.R. Vallance-Owen (Eds.).
86. Hammes H-P, Martin S, Federlin K, et al. Aminoguianidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991, 88:11555-11558.
87. Tilton RG, LaRose LS, Kilo C, et al. Absence of degenerative changes in retinal and uveal capillary pericytes in diabetic rats. Invest Ophthalmol Vis Sci 1986, 27:716-721.
88. Robison WG, Laver NM, Lou MF The role of aldose reductase in diabetic retinopathy: Prevention and intervention studies. Progress in retinal and eye research, vol. 14 1995, 593-640. Pergamon Press, Oxford. N.N. Osborne, G.J. Chader (Eds.).
89. Robison WG, Kador PF, Kinoshita JH Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor. Science 1983, 221:1177-1179.
90. Frank RN, Keirn RJ, Kennedy A, et al. Galactose-induced retinal capillary basement membrane thickening: prevention by sorbinil. Invest Ophthalmol Vis Sci 1983, 24:1519-1524.
91. Kimura T, Chen C-H, Patz A Ultrastructure of intravitreal proliferative tissue in human and puppy eyes. XXIII concilium ophthalmologicum 1979, 1553-1556. Igaku Shoin, Tokyo. K. Shimizu (Ed.).
92. Tilton RG, Pugliese G, Williamson JR Diabetes-induced glomerular changes in rats are not prevented by sorbinil. Diabetes 1989, 38(Suppl. 2):94.
93. Engerman RL, Colquhoun PJ Epithelial and mesothelial basement membranes in diabetic patients and dogs. Diabetologia 1982, 23:521-524.
94. Frank RN, Amin R, Kennedy A, et al. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Arch Ophthalmol 1997, 115:136-147.
95. Kern TS, Engerman RL Galactose-induced retinal microangiopathy in rats. Invest Ophthalmol Vis Sci 1995, 36:490-496.
96. Robison WG, Laver NM, Jacot JL, et al. Diabetic-like retinopathy ameliorated with the aldose reductase inhibitor WAY-121,509. Invest Ophthalmol Vis Sci 1996, 37:1149-1156.
97. Robison WG, McCaleb ML, Feld LG, et al. Degenerated intramural pericytes ('ghost cells') in the retinal capillaries of diabetic rats. Curr Eye Res 1991, 10:339-350.
98. Mizutani M, Kern TS, Lorenzi M Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996, 97:2883-2890.
99. Bloodworth JM, Engerman RL, Anderson PJ Microangiopathy in the experimentally diabetic animal. Adv Metab Disord 1973, 2(Suppl.):245-250.
100. Engerman RL, Kern TS Experimental galactosemia produces diabetic-like retinopathy. Diabetes 1984, 33:97-100.
101. Kador PF, Akagi Y, Takahashi Y, et al. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol 1990, 108:1301-1309.
102. Kador PF, Akagi Y, Terubayashi H, et al. Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol 1988, 106:1099-1102.
103. Kern TS, Engerman RL A mouse model of diabetic retinopathy. Arch Ophthalmol 1996, 114:986-990.
104. DeOliveira F Pericytes in diabetic retinopathy. Br J Ophthalmol 1966, 50:134-143.
105. Kern TS, Engerman RL Capillary lesions develop in retina rather than cerebral cortex in diabetes and experimental galactosemia. Arch Ophthalmol 1996, 114:306-310.
106. Frank RN, Dutta SD, Mancini MA Pericyte coverage is greater in the retinal than in the cerebral capillaries of the rat. Invest Ophthalmol Vis Sci 1987, 28:1086-1091.
107. Frank RN, Turczyn TJ, Das A Pericyte coverage of retinal and cerebral capillaries. Invest Ophthalmol Vis Sci 1990, 31:999-1007.
108. Tilton RG, Miller EJ, Kilo C, et al. Pericyte form and distribution in rat retinal and uveal capillaries. Invest Ophthalmol Vis Sci 1985, 26:68-73.
109. Patz A The role of oxygen in retrolental fibroplasias. Trans Am Ophthalmol Soc 1968, 66:940-985.
110. Kremer I, Kissun R, Nissenkorn I, et al. Oxygen-induced retinopathy in newborn kittens: a model for ischemic vasoproliferative retinopathy. Invest Ophthalmol Vis Sci 1987, 28:126-130.
111. Michaelson IC The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 1948, 68:137-180.
112. Wise GN, Dollery CT, Henkind P The retinal circulation 1971, 34-54. Harper & Row, New York, 290-324.
113. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995, 92:10457-10461.
114. Penn JS, Rajaratnan VS, Collier RJ, et al. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2001, 42:283-290.
115. Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 1997, 151:13-23.
116. Buzney SM, Frank RN, Robison WG Retinal capillaries: proliferation of mural cells in vitro. Science 1975, 190:985-986.
117. Frank RN, Kinsey VE, Frank KW, et al. In vitro proliferation of endothelial cells from kitten retinal capillaries. Invest Ophthalmol Vis Sci 1979, 18:1195-1200.
118. Bowman PD, Betz AL, Goldstein GW Primary culture of microvascular endothelial cells from bovine retina: selective growth using fibronectin coated substrate and plasma derived serum. In Vitro 1982, 118:626-632.
119. Buzney SM, Massicotte SJ Retinal vessels: proliferation of endothelium in vitro. Invest Ophthalmol Vis Sci 1979, 18:1191-1195.
120. Gitlin JD, D'Amore PA Culture of retinal capillary cells using selective growth media. Microvasc Res 1983, 26:74-80.
121. Puro DG Calcium channels of human retinal glial cells. Methods of neuroscience 1994, 68-81. Academic Press, Orlando, FL. T. Harahashi (Ed.).
122. Madri JA, Williams SK Capillary endothelial cell cultures: phenotypic modulation by matrix components. J Cell Biol 1983, 97:153-165.
123. Montesano R, Orci L, Vassalli P In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 1983, 97:1648-1652.
124. Goto F, Goto K, Weindel K, et al. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 1993, 69:508-517.
125. Orlidge A, D'Amore PA Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol 1987, 105:1455-1462.
126. Antonelli-Orlidge A, Saunders KB, Smith SR, et al. An activated form of transforming growth factor β is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 1989, 86:4544-4548.
127. Lindahl P, Johansson BR, Levéen P, et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277:242-245.
128. Herman IM, D'Amore PA Microvascular pericytes contain muscle and nonmuscle actins. J Cell Biol 1985, 101:43-52.
129. Kelley C, D'Amore P, Hechtman HB, et al. Microvascular pericyte contractility in vitro: comparison with other cells of the vascular wall. J Cell Biol 1987, 104:483-490.
130. Das A, Frank RN, Weber ML, et al. ATP causes retinal pericytes to contract in vitro. Exp Eye Res 1988, 46:349-362.
131. Kelley C, D'Amore PA, Hechtman HB, et al. Vasoactive hormones and cAMP affect pericyte contraction and stress fibres in vitro. J Muscle Res Cell Motil 1988, 9:184-194.
132. Chakravarthy U, Gardiner TA, Anderson P, et al. The effect of endothelin 1 on the retinal microvascular pericyte. Microvasc Res 1992, 43:241-254.
133. Tilton RG, Kilo C, Williamson JR, et al. Differences in pericyte contractile function in rat cardiac and skeletal muscle microvasculatures. Microvasc Res 1979, 18:336-352.
134. Butryn RK, Ruan H, Hull CM, et al. Vasoactive agonists do not change the caliber of retinal capillaries of the rat. Microvasc Res 1995, 50:80-93.
135. Das A, Frank RN, Zhang NL, et al. Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening - prevention by an aldose reductase inhibitor. Exp Eye Res 1990, 50:269-280.
136. Robison WG, Kador PF, Akagi Y, et al. Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat. Diabetes 1986, 35:295-299.
137. Das A, Frank RN, Zhang NL Sorbinil does not prevent galactose-induced glomerular capillary basement membrane thickening. Diabetologia 1990, 33:515-521.
138. Nishio Y, Warren CE, Buczek-Thomas JA, et al. Identification and characterization of a gene regulating enzymatic glycosylation which is induced by diabetes and hyperglycemia specifically in rat cardiac tissue. J Clin Invest 1995, 96:1759-1767.
139. Brownlee M, Cerami A The biochemistry of the complications of diabetes mellitus. Annu Rev Biochem 1981, 50:385-432.
140. Timpl R, Rohde H, Robey PG, et al. Laminin: a glycoprotein from basement membranes. J Biol Chem 1979, 254:9933-9937.
141. Grant DS, Kleinman HK Regulation of capillary formation by laminin and other components of the extracellular matrix. Regulation of angiogenesis 1997, 317-333. Birkhäuser Verlag, Basel, Switzerland. I.D. Goldberg, E.M. Rosen (Eds.).
142. Kennedy A, Frank RN, Mancini MA In vitro production of glycosaminoglycans by retinal microvessel cells and lens epithelium. Invest Ophthalmol Vis Sci 1986, 27:746-754.
143. Rohrbach DH, Wagner CW, Star VL, et al. Reduced synthesis of basement membrane heparan sulfate proteoglycan in streptozotocin-induced diabetic mice. J Biol Chem 1983, 258:11672-11677.
144. Pihlajaniemi T, Myllyla R, Kivirikko KI, et al. Effects of streptozotocin diabetes, glucose, and insulin on the metabolism of type IV collagen and proteoglycan in murine basement membrane-forming EHS tumor tissue. J Biol Chem 1982, 257:14914-14920.
145. Shimomura H, Spiro RG Studies on macromacular components of human glomerular basement membrane and alterations in diabetes: decreased levels of heparan sulfate proteoglycan and laminin. Diabetes 1987, 36:374-381.
146. Spiro RG, Spiro MJ Effect of diabetes on the biosynthesis of the renal glomerular basement membrane. Diabetes 1971, 20:641-648.
147. Kennedy A, Frank RN, Mancini MA, et al. Collagens of the retinal microvascular basement membrane and of retinal microvascular cells in vitro. Exp Eye Res 1986, 42:177-199.
148. Farquhar MG The glomerular basement membrane - a selective macromolecular filter. Cell biology of the extracellular matrix 1982, 335-378. Plenum Press, New York. E.D. Hay (Ed.).
149. Farquhar MG, Courtoy PJ, Lenkin MC, et al. Current knowledge of the functional architecture of the glomerular basement membrane. New trends in basement membrane research 1982, 9-30. Raven Press, New York. K. Kuehn, H.H. Schoene, R. Timpl (Eds.).
150. Pino RM, Essner E Permeability of rat choriocapillaris to hemeproteins: restriction of tracers by a fenestrated endothelium. J Histochem Cytochem 1981, 29:281-290.
151. Li W, Rockey JH Fluorescein binding to normal human serum proteins demonstrated by equilibrium dialysis. Arch Ophthalmol 1982, 100:484-487.
152. Form DM, Pratt BM, Madri JA Endothelial cell proliferation during angiogenesis: in vitro modulation by basement membrane components. Lab Invest 1986, 55:521-530.
153. Ingber DE, Folkman J How does extracellular matrix control capillary morphogenesis?. Cell 1989, 58:803-805.
154. Orlidge A, D'Amore PA Cell specific effects of glycosaminoglycans on the attachment and proliferation of vascular wall components. Microvasc Res 1986, 31:41-53.
155. Trelstad RL Glycosaminoglycans: mortar, matrix, mentor. Lab Invest 1985, 53:1-4.
156. Hall HG, Farson DA, Chin S, et al. Extracellular matrix and morphogenesis: collagen overlay induces lumen formation by epithelial cell lines. Extracellular matrix 1982, 233-238. Academic Press, New York. S. Hawkes, J.L. Wang (Eds.).
157. Kleinman HK, Klebe RJ, Martin GR Role of collagenous matrices in the adhesion and growth of cells. J Cell Biol 1981, 88:473-485.
158. Frank RN, Mancini MA Presumed retinovitreal neovascularization in dystrophic retinas of spontaneously hypertensive rats. Invest Ophthalmol Vis Sci 1986, 27:346-355.
159. Kalebic T, Garbisa S, Glaser B, et al. Basement membrane collagen: degradation by migrating endothelial cells. Science 1983, 221:281-283.
160. van Hinsbergh VWM, Koolwijk P, Hanemaaijer R Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. Regulation of angiogenesis 1997, 391-411. Birkhäuser Verlag, Basel, Switzerland. I.D. Goldberg, E.M. Rosen (Eds.).
161. Folkman J, Klagsbrun M, Sasse J, et al. A heparin-binding angiogenic protein - basic fibroblast growth factor - is stored within basement membrane. Am J Pathol 1988, 130:393-400.
162. Vigny M, Ollier-Hartmann MP, Lavigne M, et al. Specific binding of basic fibroblast growth factor to basement membrane-like structures and to purified heparan sulfate proteoglycan of the EHS tumor. J Cell Physiol 1988, 137:321-328.
163. Sakaguchi K, Yanagishita M, Takeuchi Y, et al. Identification of heparan sulfate proteoglycan as a high affinity receptor for acidic fibroblast growth factor (aFGF) in a parathyroid cell line. J Biol Chem 1991, 266:7270-7278.
164. Cogan DG, Toussaint D, Kuwabara T Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol 1961, 66:366-378.
165. Kuwabara T, Cogan DG Retinal vascular patterns. VI. Mural cells of the retinal capillaries. Arch Ophthalmol 1963, 69:492-502.
166. Kuwabara T, Cogan DG Studies of retinal vascular patterns. I. Normal architecture. Arch Ophthalmol 1960, 64:904-911.
167. Speiser P, Gittelsohn AM, Patz A Studies on diabetic retinopathy. III. Influence of diabetes on intramural pericytes. Arch Ophthalmol 1968, 80:332-337.
168. Yanoff M Diabetic retinopathy. N Engl J Med 1966, 274:1344-1349.
169. Akagi Y, Kador PF, Kuwabara T, et al. Aldose reductase localization in human retinal mural cells. Invest Ophthalmol Vis Sci 1983, 24:1516-1519.
170. Tilton RG, Hoffmann PL, Kilo C, et al. Pericyte degeneration and basement membrane thickening in skeletal muscle capillaries of human diabetics. Diabetes 1981, 30:326-334.
171. Kern TS, Engerman RL Distribution of aldose reductase in ocular tissues. Exp Eye Res 1981, 33:175-182.
172. Ludvigson MA, Sorensen RL Immunohistochemical localization of aldose reductase. II. Rat eye and kidney. Diabetes 1980, 29:450-459.
173. Kennedy A, Frank RN, Varma SD Aldose reductase activity in retinal and cerebral microvessels and cultured vascular cells. Invest Ophthalmol Vis Sci 1983, 24:1250-1258.
174. Buzney SM, Frank RN, Varma SD, et al. Aldose reductase in retinal mural cells. Invest Ophthalmol Vis Sci 1977, 16:392-396.
175. Friedenwald JS Diabetic retinopathy. Am J Ophthalmol 1950, 33:1187-1199.
176. Joyce NC, DeCamilli P, Boyles J Pericytes, like vascular smooth muscle cells, are immunocytochemically positive for cyclic GMP-dependent protein kinase. Microvasc Res 1984, 28:206-219.
177. Ashton N, Kok D'A, Foulds WS Ocular pathology in macroglobulinaemia. J Pathol Bacteriol 1963, 86:453-461.
178. Duke JR, Wilkinson CP, Sigelman S Retinal microaneurysms in leukaemia. Br J Ophthalmol 1968, 52:368-374.
179. DeVenecia G, Davis MD Histology and fluorescein angiography of microaneurysms in diabetes mellitus. Invest Ophthalmol 1967, 6:555.
180. Kohner EM, Henkind P Correlation of fluorescein angiogram and retinal digest in diabetic retinopathy. Am J Ophthalmol 1970, 69:403-414.
181. Wallow IHL, Engerman RL Permeability and patency of retinal blood vessels in experimental diabetes. Invest Ophthalmol Vis Sci 1977, 16:447-461.
182. Gardner TW, Lesher T, Khin S, et al. Histamine reduces ZO-1 tight-junction protein expression in cultured retinal microvascular endothelial cells. Biochem J 1996, 320:717-721.
183. Gardner TW Histamine, ZO-1 and increased blood-retinal barrier permeability in diabetic retinopathy. Trans Am Ophthalmol Soc 1995, 93:583-621.
184. 1 receptors mediate increased blood-retinal barrier permeability in experimental diabetes. Arch Ophthalmol 1989, 107:270-274.
185. Gardner TW, Eller AW, Friberg TR, et al. Antihistamines reduce blood-retinal barrier permeability in type I (insulin-dependent) diabetic patients with nonproliferative retinopathy. A pilot study. Retina 1995, 15:134-140.
186. Barber AJ, Antonelli DA, Gardner TW Altered expression of retinal occludin and glial fibrillary acid protein in experimental diabetes. The Penn State Retinal Research Group. Invest Ophthalmol Vis Sci 2000, 41:3561-3568.
187. Antonetti DA, Barber AJ, Hollinger LA, et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occludens-1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999, 274:23463-23467.
188. Lakshminarayan S, Antonetti DA, Gardner TW, et al. Effect of VEGF on retinal microvascular endothelial hydraulic conductivity: the role of NO. Invest Ophthalmol Vis Sci 2000, 41:4256-4261.
189. Sorbinil Retinopathy Trial Research Group A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990, 108:1234-1244.
190. Wallow IHL, Geldner PS Endothelial fenestrae in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1980, 19:1176-1183.
191. Essner E Role of vesicular transport in breakdown of the blood-retinal barrier. Lab Invest 1987, 56:457-460.
192. Essner E, Pino RM, Griewski RA Breakdown of blood retinal barrier in RCS rats with inherited retinal degeneration. Lab Invest 1980, 43:418-426.
193. Davis MD, Norton EWD, Myers FL The Airlie classification of diabetic retinopathy. Symposium on the treatment of diabetic retinopathy. US Public Health Service publication no. 1890 1968, 7-22. US Government Printing Office, Washington, DC, . M.F. Goldberg, S.L. Fine (Eds.).
194. DeVenecia G, Davis M, Engerman R Clinicopathologic correlations in diabetic retinopathy. I. Histology and fluorescein angiography of microaneurysms. Arch Ophthalmol 1976, 94:1766-1773.
195. Brownlee M, Vlassara H, Kooney A, et al. Aminoguanidine prevents diabetes- induced arterial wall protein cross-linking. Science 1986, 232:1629-1632.
196. Tesfamariam B Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med 1994, 16:383-391.
197. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 1996, 98:1667-1675.
198. Du Y, Smith MA, Miller CM, et al. Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem 2002, 80:771-779.
199. Kunisaki M, Bursell SE, Clermont AC, et al. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am J Physiol 1995, 269(2 Pt 1):E239-E246.
200. Kowluru RA, Tang J, Kern TS Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001, 50:1938-1942.
201. Joussen AM, Murata T, Tsujikawa A, et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001, 158:147-152.
202. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002, 16:438-440.
203. Adamis AP Is diabetic retinopathy an inflammatory disease?. Br J Ophthalmol 2002, 86:363-365.
204. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002, 109:920-927.
205. Early Treatment Diabetic Retinopathy Study Research Group Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Ophthalmology 1991, 98(Suppl.):757-765.
206. Kern TS, Engerman RL Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 2001, 50:1636-1642.
207. Engerman RL, Kern TS Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987, 36:808-812.
208. Engerman RL, Kern TS Retinopathy in galactosemic dogs continues to progress after cessation of galactosemia. Arch Ophthalmol 1994, 113:355-358.
209. Aiello LP, Robinson GS, Lin YW, et al. Identification of multiple genes in bovine retinal pericytes altered by exposure to elevated levels of glucose by using mRNA differential display. Proc Natl Acad Sci USA 2004, 91:6231-6235.
210. Gabbay KH The sorbitol pathway and the complications of diabetes. N Engl J Med 1973, 288:831-836.
211. Kinoshita JH Cataracts in galactosemia. Invest Ophthalmol 1965, 4:786-799.
212. Robison WG Aldose reductase inhibition and retinopathy (letter to the editor). Diabetes 1994, 43:337-338.
213. Engerman RL, Kern TS Response to Robison (letter to the editor). Diabetes 1994, 43:338-339.
214. Frank RN Perspectives in diabetes. The aldose reductase controversy. Diabetes 1994, 43:169-172.
215. Engerman RL Pathogenesis of diabetic retinopathy. Diabetes 1989, 38:1203-1206.
216. Kern TS, Engerman RL Retinal polyol and myo-inositol in galactosemic dogs given an aldose reductase inhibitor. Invest Ophthalmol Vis Sci 1991, 32:3175-3177.
217. Lee AY, Chung SK, Chung SS Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc Natl Acad Sci USA 1995, 92:2780-2784.
218. Xia P, Inoguchi T, Kern T, et al. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994, 43:1122-1129.
219. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996, 98:2018-2026.
220. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996, 272:728-731.
221. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997, 46:1473-1480.
222. Milton R, Aiello L, Davis M, et al. Initial results of the protein kinase C β inhibitor diabetic retinopathy study (PKC-DRS). Diabetes 2003, 52(Suppl. 1):A-127. (abstract no. 544-P).
223. Campochiaro PA and the C99-PKC 412-003 Study Group Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC 412. Invest Ophthalmol Vis Sci 2004, 45:922-931.
224. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003, 9:294-299.
225. King GL, Buzney SM, Kahn CR, et al. Differential responsiveness to insulin of endothelial and support cells from micro- and macrovessels. J Clin Invest 1983, 71:974-979.
226. Engerman RL, Pfaffenbach D, Davis MD Cell turnover of capillaries. Lab Invest 1967, 17:738-743.
227. Kumagai AK, Glasgow BJ, Pardridge WM GLUT1 glucose transporter expression in the diabetic and nondiabetic human eye. Invest Ophthalmol Vis Sci 1994, 35:2887-2894.
228. Kumagai AK, Vinores SA, Pardridge WM Pathological upregulation of inner blood-retinal barrier GLUT1 glucose transporter expression in diabetes mellitus. Brain Res 1996, 706:313-317.
229. Mantych GJ, Hageman GS, Devaskar SU Characterization of glucose transporter isoforms in the adult and developing human eye. Endocrinology 1993, 133:600-607.
230. Watanabe T, Mio Y, Hoshino FB, et al. GLUT2 expression in the rat retina: localization at the apical ends of Müller cells. Brain Res 1994, 65:128-134.
231. Watanabe T, Matsushima S, Okazaki M, et al. Localization and ontogeny of GLUT3 expression in the rat retina. Dev Brain Res 1996, 94:60-66.
232. Burgess WH, Maciag T The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989, 58:575-606.
233. Gospodarowicz D Purification of a fibroblast growth factor from bovine pituitary. J Biol Chem 1975, 250:2515-2520.
234. Neufeld G, Gospodarowicz D Basic and acidic fibroblast growth factors interact with the same cell surface receptors. J Biol Chem 1986, 261:5631-5637.
235. Glaser BM, D'Amore PA, Michels RG, et al. Demonstration of vasoproliferative activity from mammalian retina. J Cell Biol 1980, 84:298-304.
236. Baird A, Esch F, Gospodarowicz D Retina- and eye-derived endothelial cell growth factors: partial molecular characterization and identity with acidic and basic fibroblast growth factors. Biochemistry 1985, 24:7855-7860.
237. Schreiber AB, Kenney J, Kowalski JR, et al. A unique family of endothelial cell polypeptide mitogens: the antigenic and receptor cross-reactivity of bovine endothelial cell growth factor, brain-derived acidic fibroblast growth factor, and eye-derived growth factor-II. J Cell Biol 1985, 101:1623-1626.
238. Abraham JA, Mergia A, Whang JL, et al. Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 1986, 233:541-545.
239. Vlodavsky I, Fridman R, Sullivan R, et al. Aortic endothelial cells synthesize basic fibroblast growth factor which remains cell associated and platelet-derived growth factor-like protein which is secreted. J Cell Physiol 1987, 13:402-408.
240. Amin R, Puklin JE, Frank RN Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci 1994, 35:3178-3188.
241. Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996, 122:393-403.
242. Hanneken A, de Juan E, Lutty GA, et al. Altered distribution of basic fibroblast growth factor in diabetic retinopathy. Arch Ophthalmol 1991, 109:1005-1011.
243. Folkman J, Klagsbrun M Angiogenic factors. Science 1987, 235:442-447.
244. Glaser BM Extracellular modulating factors and the control of intraocular neovascularization. Arch Ophthalmol 1988, 106:603-607.
245. Schweigerer L, Neufeld G, Friedman J, et al. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 1987, 325:257-259.
246. Sivalingam A, Kenney J, Brown GC, et al. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1990, 108:869-872.
247. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994, 112:1476-1482.
248. Brown LF, Detmar M, Claffey K, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. Regulation of angiogenesis 1997, 233-269. Birkhäuser Verlag, Basel. I.D. Goldberg, E.M. Rosen (Eds.).
249. Mathews MK, Merges C, McLeod DS, et al. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci 1997, 38:2729-2741.
250. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
251. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995, 113:1538-1544.
252. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor (VEGF) by retinal cells is a common factor in neovascularization. Lab Invest 1995, 72:638-645.
253. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994, 331:1480-1487.
254. Adamis AP, Miller JW, Bernal M-T, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994, 118:445-450.
255. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994, 145:574-584.
256. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996, 114:66-71.
257. Robinson GS, Pierce EA, Rook SL, et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 1996, 93:4851-4856.
258. Lutty GA, McLeod DS, Merges C, et al. Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol 1996, 114:971-977.
259. Amin RH, Frank RN, Kennedy A, et al. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1997, 38:36-47.
260. Hanneken A, Lutty GA, McLeod DS, et al. Localization of basic fibroblast growth factor to the developing capillaries of the bovine retina. J Cell Physiol 1989, 138:115-120.
261. Noji S, Matsuo T, Koyama E, et al. Expression pattern of acidic and basic fibroblast growth factor genes in adult rat eyes. Biochem Biophys Res Commun 1990, 168:343-349.
262. Schweigere L, Malerstein B, Neufeld G, et al. Basic fibroblast growth factor is synthesized in cultured retinal pigment epithelial cells. Biochem Biophys Res Commun 1987, 143:934-940.
263. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439.
264. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439-442.
265. Danis RP, Bingaman DP, Jrousek M, et al. Inhibition of intraocular neovascularization due to retinal ischemia in pigs by PKCβ inhibition with LY333531. Invest Ophthalmol Vis Sci 1998, 39:171-179.
266. Eyetech Study Group Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003, 110:979-986.
267. Ferrara N Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002, 29(Suppl. 16):10-14.
268. Rosen LS Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002, 9(Suppl. 2):36-44.
269. Slakter JS, the Anecortave Acetate Clinical Study Group Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: 12-month clinical outcomes. Ophthalmology 2003, 110:2372-2383.
270. Steele FR, Chader GJ, Johnson LV, et al. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci USA 1993, 90:1526-1530.
271. Ogata N, Wada M, Otsuji T, et al. Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2002, 43:1168-1175.
272. Becerra SP, Wu YQ, Montuenga L, et al. Pigment epithelium-derived factor (PEDF) in the monkey eye: apical secretion from the retinal pigment epithelium. Invest Ophthalmol Vis Sci 2001, 42:S772.
273. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999, 155:421-428.
274. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999, 285:245-248.
275. Stellmach V, Crawford SE, Zhou W, et al. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 2001, 98:2593-2597.
276. Gao G, Li Y, Zhang D, et al. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 2001, 489:270-276.
277. GVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001, 12:2029-2032.